



For Immediate Release

Media Contact

Thomas Shaffer

Vice President, Marketing

732-661-2522

**MTF Announces Receipt of 510(k) PreMarket Clearance from FDA for DBX®
Demineralized Bone Matrix**

Edison, NJ, April 5, 2005 ---- The Musculoskeletal Transplant Foundation (MTF) has received a 510(k) PreMarket Notification (K040262) from the FDA to market their DBX brand of Demineralized Bone Matrix. DBX is available in *Putty*, *Paste* and *Mix* formulations.

DBX is intended for use as a Demineralized Bone Matrix for voids or gaps that are not intrinsic to the stability of the bony structure. It is indicated for the treatment of surgically created osseous defects or osseous defects created from traumatic injury. DBX Paste, Putty and Mix are indicated for a variety of uses in Extremities, Spine, Pelvis and Cranium.

As a part of the FDA requirements for Demineralized Bone Matrix under the medical device rule, each lot of DBX is tested for osteoinductivity through a validated in-vivo model. DBX is also validated for viral inactivation.

Since the launch of the tissue form in October 2000, DBX has quickly become the leading Demineralized Bone Matrix of choice for orthopedic surgeons in the United States and is quickly gaining popularity in international markets.

About Musculoskeletal Transplant Foundation

The Musculoskeletal Transplant Foundation is the nation's largest tissue bank and non-profit service organization dedicated to providing quality tissue through a commitment of excellence in education, research, recovery and care for recipients, donors and their families. In 2004, MTF distributed over 340,000 grafts assisting more than 225,000 patients. The Musculoskeletal Transplant Foundation is a service organization dedicated to the advancement of bone, ligament and cartilage transplantation.